HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia
Open accessThe DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index; 22 of the 45 sources its claims cite were checked for support.
Abstract
Although originally described as transcriptional activator, SPI1/PU.1, a major player in haematopoiesis whose alterations are associated with haematological malignancies, has the ability to repress transcription. Here, we investigated the mechanisms underlying gene repression in the erythroid lineage, in which SPI1 exerts an oncogenic function by blocking differentiation. We show that SPI1 represses genes by binding active enhancers that are located in intergenic or gene body regions. HDAC1 acts as a cooperative mediator of SPI1-induced transcriptional repression by deacetylating SPI1-bound enhancers in a subset of genes, including those involved in erythroid differentiation. Enhancer deacetylation impacts on promoter acetylation, chromatin accessibility and RNA pol II occupancy. In addition to the activities of HDAC1, polycomb repressive complex 2 (PRC2) reinforces gene repression by depositing H3K27me3 at promoter sequences when SPI1 is located at enhancer sequences. Moreover, our study identified a synergistic relationship between PRC2 and HDAC1 complexes in mediating the transcriptional repression activity of SPI1, ultimately inducing synergistic adverse effects on leukaemic cell survival. Our results highlight the importance of the mechanism underlying transcriptional repression in leukemic cells, involving complex functional connections between SPI1 and the epigenetic regulators PRC2 and HDAC1.
Overview
CoChat Summary
TL;DR
SPI1/PU.1 represses genes in murine erythroleukaemia mainly by binding active enhancers in intergenic or gene-body regions, where it cooperates with HDAC1 to deacetylate enhancers and with PRC2 to reinforce repression via H3K27me3. Combined HDAC1 and PRC2 inhibition synergistically reactivates SPI1-repressed erythroid genes and kills TgSpi1 leukaemic cells.
Key findings
- RNA-seq after 48 h doxycycline-induced Spi1 knockdown identified 1,579 differentially expressed genes: 972 activated and 607 repressed in the presence of SPI1. SPI1 bound 57% of repressed genes and 66% of activated genes, versus 25% of NoResp genes.
- SPI1-repressed genes were enriched for SPI1 peaks in intergenic regions (×1.5), distal promoters (×1.8), and gene bodies (×2.5), with no enrichment near TSS. Among SPI1-bound intergenic/gene-body regions of repressed genes, 90% contained H3K4me1; 53% (#763) and 58% (#722) were active enhancers. Deleting a SPI1 motif in the Alas2 enhancer reduced SPI1 occupancy and increased Alas2 mRNA.
- HDAC1 was identified as a SPI1 partner. 159 of 264 (60%) SPI1-repressed enhancer-bound genes were also repressed by HDAC1 (odds ratio 6, Fisher exact P ≈ 3.5 × 10−35); only 8% of SPI1-activated genes were also activated by HDAC1. HDAC1 inhibition reduced SPI1-mediated repression, and HDAC1 occupied deacetylated SPI1-bound enhancers.
- SPI1 occupancy at deacetylated enhancers was associated with increased H3K27me3 around TSS, and SPI1 stimulated PRC2-mediated H3K27 trimethylation in vitro. Combined HDAC1/PRC2 inhibition synergistically increased expression of Alas2, St3gal6, Sox6, and Nprl3 and synergistically reduced leukaemic cell survival; no synergy was observed in A20, K562, or KG1 cells.
Methods
- Murine TgSpi1 erythroleukaemic cells (#763, #722, #683) with doxycycline-inducible Spi1 shRNA were used, plus HEK293T, KG1, K562, and A20 cells. CRISPR-Cas9 generated enhancer deletions and a SPI1-motif mutation in the Alas2 enhancer. Inhibitors included entinostat (HDAC1/3), UNC1999 (EZH1/2), and TMP195.
- Genome-wide assays included RNA-seq, ChIP-seq (SPI1, H3K27ac, H3K4me1, H3K27me3, H3K4me3, RNA pol II), ATAC-seq, HDAC1 CUT&Tag, 4C-seq, and RIME mass spectrometry. Validation used co-immunoprecipitation, immunoblotting, RT-qPCR, flow cytometry, methylcellulose/benzidine differentiation assays, and in vitro PRC2 methyltransferase assays.
- Analyses included differential expression, peak annotation, ChromHMM chromatin states, Fisher’s exact tests, motif enrichment, correlation with expression, and ZIP synergy scoring for drug combinations.
Limitations
- The paper states that more research is needed to determine whether SPI1 recruits or stabilizes HDAC1 or improves its activity in erythroleukaemic cells, and that further studies are needed to understand repression of the HDAC1-independent subgroup of genes.
- The authors note that combined HDAC1/PRC2 inhibition was not sufficient to reverse erythroid differentiation blockage unless SPI1 was also depleted, suggesting additional SPI1-dependent, HDAC1/PRC2-independent functions. They also state it would be interesting to test whether combined HDAC and PRC2 inhibitors show specific sensitivity in primary human AEL cells.
- Evident from the text: most mechanistic work uses murine TgSpi1 erythroleukaemic cells and cell lines, with pharmacological inhibitors that may have off-target effects; the study does not establish direct recruitment of PRC2 by SPI1 at chromatin, relying on interaction and in vitro activity data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
12 Valid · 0 Not valid · 16 Not checked · 180 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“we showed that polycomb repressive complex 2 (PRC2), an epigenetic modifier complex that controls the repressive trimethylation of H3K27 (H3K27me3) (32,33), is involved in the transcriptional repression of the proapoptotic encoding gene Bcl2l11 by SPI1 in erythroleukaemia (23)”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > INTRODUCTION
What the sources say
- Supportedcites [23] Ridinger-Saison M., Evanno E., Gallais I., Rimmele P., Selimoglu-Buet D., Sapharikas E., Moreau-Gachelin F., Guillouf C. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ. 2013; 20: 1268– 1278. 23852375 PMC3741512 source
The paper's summary/abstract states that Spi-1 overexpression promotes resistance to apoptosis in erythroleukaemia and that Spi-1 represses Bim transcription via H3K27me3 at the Bim promoter, with 'The PRC2 repressive complex of Polycomb is directly responsible for the deposit of H3K27me3 mark at the Bim promoter' (Bcl2l11 being the gene encoding Bim). The Discussion (p. unnumbered) reinforces this: SUZ12/EZH2 bind the Bim promoter at the H3K27me3 sites and both Spi-1 and PRC2 are required for the mark, i.e. PRC2 is involved in SPI1-mediated repression, though the paper notes Spi-1 modulates PRC2 activity rather than demonstrably recruiting it. The citing paraphrase carries no stronger claim than this. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“SPI1/PU.1, a major player in haematopoiesis whose alterations are associated with haematological malignancies, has the ability to repress transcription.”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > Abstract
What the sources say
- Not checked yetcites [14] Fischer J., Walter C., Tonges A., Aleth H., Jordao M.J.C., Leddin M., Groning V., Erdmann T., Lenz G., Roth J. et al. Safeguard function of PU.1 shapes the inflammatory epigenome of neutrophils. Nat. Immunol. 2019; 20: 546– 558. 30911105 source
- Supportedcites [15] Hosokawa H., Ungerbäck J., Wang X., Matsumoto M., Nakayama K.I., Cohen S.M., Tanaka T., Rothenberg E.V. Transcription factor PU.1 represses and activates gene expression in early T cells by redirecting partner transcription factor binding. Immunity. 2018; 48: 1119– 1134. 29924977 PMC6063530 source
Our copy states the attributed point explicitly and repeatedly: the Introduction records that 'PU.1 activates and represses approximately equal numbers of genes in pro-T cells' and frames hematopoietic lineage-determining transcription factors as 'bifunctional... repressing as well as activating'; the Abstract and Discussion confirm genes 'that PU.1 represses' and that 'the mode of repression we have shown for PU.1 here is repression at a distance'. The citing sentence's incidental clauses (major role in haematopoiesis, association with haematological malignancies) are the citing authors' background framing and are not the point offered to this source; the repression capacity itself is directly supported. (LLM, conf=0.90)
- Supportedcites [16] Ungerbäck J., Hosokawa H., Wang X., Strid T., Williams B.A., Sigvardsson M., Rothenberg E.V. Pioneering, chromatin remodeling, and epigenetic constraint in early T-cell gene regulation by SPI1 (PU.1). Genome Res. 2018; 28: 1508– 1519. 30171019 PMC6169891 source
The Results section ('Pioneering by PU.1 in DN3-like cells') states that PU.1 introduction repressed many genes in early pro-T cells, that this repression could start early (2 h vs 8 h for positive targets), and that although much was likely indirect, some was accompanied by direct binding — e.g. Il7r substantially repressed as PU.1 bound an open Group 4 site at its promoter. The Discussion reinforces this, identifying 'a minority of negative regulation targets that are also likely to be direct' alongside the core positively regulated group, and referring to the obligate-repressor PU1ENGHA form. Thus our copy supports the attributed point that SPI1/PU.1 can repress transcription; the surrounding framing about haematopoiesis and malignancies is the citing authors' own context, not judged here. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Such a difference in GATA1 and SPI1 co-binding between the two types of SPI1-bound enhancers was also seen using GATA1 peaks from G1E-ER4 restored for GATA1 activity (64,65) or Ter119+ foetal liver proerythroblasts (66) (Supplementary Figure S9A), revealing a specific enrichment for GATA1 binding sites at SPI1-deacetylated enhancers.”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > RESULTS > SPI1 represses enhancers that are enriched for GATA1
What the sources say
- Supportedcites [64] Cheng Y., Wu W., Kumar S.A., Yu D., Deng W., Tripic T., King D.C., Chen K.B., Zhang Y., Drautz D. et al. Erythroid GATA1 function revealed by genome-wide analysis of transcription factor occupancy, histone modifications, and mRNA expression. Genome Res. 2009; 19: 2172– 2184. 19887574 PMC2792182 source
The part attributed to this source is the genome-wide GATA1 occupancy data set generated in G1E-ER4 cells after restoration/activation of GATA1, and our copy is exactly that study: the Abstract/Results ('Occupancy of DNA segments by GATA1 in G1E-ER4 cells') state that GATA1 ChIP was performed on G1E-ER4 cells 24 h after activation of the GATA1-ER hybrid protein, yielding ChIP-seq peaks (14,351 OSs by MACS) plus ChIP-chip peaks merged into a union set of 15,360 GATA1 OSs. The comparison of GATA1/SPI1 co-binding between two classes of SPI1-bound enhancers and the 'SPI1-deacetylated' enrichment are the citing authors' own re-analysis, not claims about this paper; our copy contains no SPI1/PU.1 or deacetylation content (searched: SPI1 PU.1 co-binding, Ter119 fetal liver proerythroblasts), and no Ter119+ fetal liver data — consistent with that material being credited to the separate citation (66). (LLM, conf=0.85)
- Supportedcites [65] Han G.C., Vinayachandran V., Bataille A.R., Park B., Chan-Salis K.Y., Keller C.A., Long M., Mahony S., Hardison R.C., Pugh B.F. Genome-wide organization of GATA1 and TAL1 determined at high resolution. Mol. Cell. Biol. 2016; 36: 157– 172. 26503782 PMC4702602 source
The citation here identifies a dataset the citing authors used — GATA1 peaks from G1E-ER4 cells restored for GATA1 activity — rather than the SPI1 co-binding comparison itself. Our copy is exactly that: it reports genome-wide GATA1 binding locations (peak pairs / MultiGPS locations, ~47,000 candidate cross-linking points and ~10,290 locations, ~8,000 WGATAA sites) in mouse G1E-ER4 cells, where GATA1 was knocked out and reintroduced as an estradiol-inducible GATA1-ER, examined at 0, 3 and 24 h of GATA1 activation (RESULTS, p.1; 'GATA1 and TAL1 locations determined by ChIP-exo'; Cell culture, Materials and Methods). Our copy contains no SPI1, Ter119 or fetal-liver proerythroblast analysis and no discussion of SPI1-deacetylated enhancers, which is consistent with its role as a data source rather than as the origin of the comparative finding; the G1E-ER4-only scope is not contrary to anything attributed to it. (LLM, conf=0.82)
- Supportedcites [66] Wu W., Cheng Y., Keller C.A., Ernst J., Kumar S.A., Mishra T., Morrissey C., Dorman C.M., Chen K.B., Drautz D. et al. Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration. Genome Res. 2011; 21: 1659– 1671. 21795386 PMC3202283 source
The citation is offered for the source of the GATA1 peak set in Ter119+ fetal liver erythroid cells, and our copy is that source: in 'Epigenetic features determined during erythroid differentiation' the authors state they 'performed ChIP-seq assays for occupancy by TAL1 and GATA1 in primary erythroblasts isolated from mouse fetal liver using the cell surface marker Ter119,' and Table 1 (Methods) lists 8,867 GATA1 peaks for Ter119+ cells (110,964,491 mapped reads), with Fig. 1A,B showing the GATA1/TAL1 profiles and peak overlaps for Ter119+ primary erythroblasts. The GATA1 peaks for G1E-ER4 cells restored for GATA1 activity are likewise reported here (Table 1: 11,491 GATA1 peaks in G1E-ER4+E2), so both datasets named in the sentence exist in this paper; the difference in GATA1-SPI1 co-binding between enhancer types is the citing authors' own analysis using these peaks, not a point this paper had to make (our copy contains no SPI1/PU.1 co-binding analysis, and it terms the Ter119+ population differentiated erythroblasts rather than proerythroblasts). (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPI1 and PRC2 interact physically (23,85), and SPI1 is able to favour PRC2 activity, at least in vitro.”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > DISCUSSION
What the sources say
- Supportedcites [23] Ridinger-Saison M., Evanno E., Gallais I., Rimmele P., Selimoglu-Buet D., Sapharikas E., Moreau-Gachelin F., Guillouf C. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ. 2013; 20: 1268– 1278. 23852375 PMC3741512 source
In the Results subsection 'Downregulation of Bim in preleukaemic cells is due to transcriptional repression by Spi-1.', the paper states that co-IP showed EZH2 and SUZ12 interact with Spi-1 and that 'these results suggest that Spi-1 promotes the PRC2 activity on histone 3', with PRC2 binding at H3K27me3 sites distinct from the Spi-1 motif — matching both the physical interaction and the promotion of PRC2 activity. The Discussion reinforces this: 'As both Spi-1 and PRC2 are required to favour H3K27m3 at the Bim promoter' and 'our results provide evidence that a transcription factor can modulate the activity of PRC2 and epigenetic regulation without recruiting PRC2 at the site of its activity on the chromatin.' All evidence is from cell-based (in vitro) erythroid progenitor systems, consistent with the citing sentence's 'at least in vitro' qualifier; only the precise mechanism (recruitment vs. stabilisation) remains speculative in the source, which the claim does not assert. (LLM, conf=0.85)
- Partly supportedcites [85] Cheng J.X., Chen L., Li Y., Cloe A., Yue M., Wei J., Watanabe K.A., Shammo J.M., Anastasi J., Shen Q.J. et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat. Commun. 2018; 9: 1163. 29563491 PMC5862959 sourceExperimental — accuracy not yet measured
Our copy supports only the physical-interaction half of the sentence: in the Results section 'RNA/hnRNPK mediates TF−chromatin modifier interactions' (Fig. 4a), 'SPI1/PU.1 specifically interacted with DNMT1 and EZH2' in OCI-M2 cells, and RNase-digestion-coupled co-IP showed 'the SPI1/PU.1−EZH2 interaction was unaffected by RNase' (Fig. 4d), i.e. a direct, RNA-independent binding. Nothing in our copy reports an in vitro PRC2/EZH2 methyltransferase activity assay or that SPI1/PU.1 stimulates (favours) PRC2 enzymatic activity; searches for 'EZH2 activity', 'H3K27', 'methyltransferase assay', 'recombinant SPI1 stimulation' returned only binding/interaction and 5-AZA-sensitivity data. The claim that SPI1 enhances PRC2 activity in vitro is therefore not supported by this source. (LLM, conf=0.70)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPI1 and PRC2 interact physically (23,85), and SPI1 is able to favour PRC2 activity, at least in vitro.”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > DISCUSSION
What the sources say
- Supportedcites [23] Ridinger-Saison M., Evanno E., Gallais I., Rimmele P., Selimoglu-Buet D., Sapharikas E., Moreau-Gachelin F., Guillouf C. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ. 2013; 20: 1268– 1278. 23852375 PMC3741512 source
In the section ‘Downregulation of Bim in preleukaemic cells is due to transcriptional repression by Spi-1’ (page not supplied), co-immunoprecipitation assays indicated that EZH2 and SUZ12, components of PRC2, interact with Spi-1. This supports the cited claim of a physical interaction. (LLM, conf=0.92)
- Partly supportedcites [85] Cheng J.X., Chen L., Li Y., Cloe A., Yue M., Wei J., Watanabe K.A., Shammo J.M., Anastasi J., Shen Q.J. et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat. Commun. 2018; 9: 1163. 29563491 PMC5862959 sourceExperimental — accuracy not yet measured
In Results, under “RNA/hnRNPK mediates TF−chromatin modifier interactions” (page unavailable), co-IP shows SPI1/PU.1 interacting with EZH2 in OCI-M2 cells, supporting a physical association with a PRC2 component. The paper does not establish an interaction with the PRC2 complex as a whole, and reports no SPI1/PU.1–EZH2 interaction in SC cells. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
152 more claims
Create a free account to see all 208 claims and to verify the 23 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Association between PU.1 and this repressive complex has previously been suggested to represent an endogenous defense mechanism in erythroid cells that restricts leukemia-associated gene expression and survival (Gregoricchio et al., 2022; Suzuki et al., 2003).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Gregoricchio et al., 2022
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The proteins MECP2, HDAC1, SIN3A, and DNMT3A that were increased after A11 treatment belong to transcriptional co-repressor complexes known to interact with PU.1 (Gregoricchio et al., 2022; Hallier et al., 1996).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Gregoricchio et al., 2022
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while the pulldown of MECP2 (Gregoricchio et al., 2022; Hallier et al., 1996) was increased by ∼150% (P = 0.0050).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Gregoricchio et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Sixty-nine genes displayed a SPI1 peak in the intergenic region, of which 45% (35/69) displayed no other peak elsewhere”
§ HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia > RESULTS > SPI1 represses gene transcription through binding to active enhancers
Reported 45 · recomputed 50.724638
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · cited 4×
“This action gives instructions to create a new enhancer with monomethylation of lysine 4 of histone 3 (H3K4me1) and to recruit additional TFs at enhancer sites (6,7).”
BackgroundInfluentialHigh-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845 · cited 1×
“The quality and sensitivity of ATAC-seq and RNA pol II ChIPseq were evaluated by the correlation of the signal at the TSS with the level of gene expression in leukaemic cells (61).”
MethodGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 8×
“However, PRC2 activity has also been shown to be required for RUNX1ETO9a or MLL-AF9 leukaemic cell growth, revealing a dual role for PRC2 in AML and its interest as a therapeutic target for certain types of leukaemia (88–90).”
BackgroundInfluentialRole of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens
Concordet, J.-P., & Haeussler, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky354 · Cited by 2,655
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., Satpathy, A. T., Rubin, A. J., Montine, K. S., Wu, B., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4396 · Cited by 2,496
Combinatorial patterns of histone acetylations and methylations in the human genome
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Peng, W., Zhang, M. Q., et al. (2008) · Nature Genetics · doi:10.1038/ng.154 · Cited by 2,331
CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing
Labun, K., Montague, T. G., Krause, M., Torres Cleuren, Y. N., Tjeldnes, H., & Valen, E. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz365 · Cited by 2,054
Cited by
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application
Chen, Y., Liang, R., Li, Y., Jiang, L., Ma, D., Luo, Q., & Song, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02030-9 · Cited by 223
Pioneer factors: roles and their regulation in development
Barral, A., & Zaret, K. S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.10.007 · Cited by 150
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
“The proteins MECP2, HDAC1, SIN3A, and DNMT3A that were increased after A11 treatment belong to transcriptional co-repressor complexes known to interact with PU.1 (Gregoricchio et al., 2022; Hallier et al., 1996).”
InfluentialKneppers, J., Severson, T., Siefert, J. C., Schol, P. J., Joosten, S. E. P., Yu, I. P. L., Huang, C.-C. F., Morova, T., Altıntaş, U. B., Giambartolomei, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35135-2 · Cited by 22
Self-citationMayayo‐Peralta, I., Gregoricchio, S., Schuurman, K. G., Yavuz, S., Zaalberg, A., Kojic, A., Abbott, N., Geverts, B., Beerthuijzen, S., Siefert, J. C., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad267 · Cited by 23
Self-citation
Metadata
- Authors
- Gregoricchio, S., Polit, L., Esposito, M., Berthelet, J., Delestré, L., Evanno, E., Diop, M., Gallais, I., Aleth, H., Poplineau, M., Zwart, W., Rosenbauer, F., Rodrigues-Lima, F., Duprez, E., Boeva, V., & Guillouf, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- University of Münster (DE)
- The Netherlands Cancer Institute (NL)
- Université Paris Cité , CNRS UMR8251, F-75013 Paris , France
- Corresponding author
- Boeva, Valentina
- Guillouf, Christel
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-07-25
- Volume
- 50
- Issue
- 14
- Pages
- 7938-7958
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC9371914
- OpenAlex
- W4286797705
- Semantic Scholar
- d9fa3654f1e632917be98aa9faa5394a28add2b6
- Cited by
- 27
- References
- 97
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 4 · 2023: 8 · 2022: 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL AMU (submittedVersion, cc-by-nc)
- HAL AMU (submittedVersion, other-oa)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc)
- ETH Zürich Research Collection
- Funders
- Inserm
- CNRS
- Ligue Nationale contre le Cancer
- Institut National Du Cancer (20141PLBIO-06-1)
- Société Française d’Hématologie
- Gustave Roussy Genomic Core Facilities (TA2019)
- Institut Thématique Multi-Organisme-Cancer de l’Alliance Nationale pour les Sciences de la Vie et de la Santé (C13104L)
- ATIP-Avenir
- ARC Foundation (ARC-RAC16002KSA-R15093KS)
- ‘Who Am I?’ Laboratory of Excellence (ANR-11-LABX-0071)
- French Government
- French National Research Agency (ANR-11-IDEX-0005-02)
- Ministère de l’Enseignement Supérieur
- Région Ile-de-France (17012698)
- Université Paris Cité
- Excellence Initiative of Aix-Marseille University
- Fondation de France (2017-00076284)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- HDAC1, polycomb repressive complex 2, gene repression, H3K27me3, erythroid differentiation, chromatin accessibility, RNA polymerase II occupancy, transcriptional repression, epigenetic regulation
- MeSH terms
- Proto-Oncogene Protein Spi-1, Acetylation, Animals, Chromatin, Leukemia, Erythroblastic, Acute, Promoter Regions, Genetic, Proto-Oncogene Proteins, Trans-Activators, Mice, Histone Deacetylase 1, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.